NCT03360110 is a NA clinical trial of Phoebe test lens in Myopia, sponsored by CooperVision, Inc..

Who is sponsoring NCT03360110?

NCT03360110 is sponsored by CooperVision, Inc..

What drugs are being tested in NCT03360110?

Interventions in NCT03360110: Phoebe test lens, stenfilcon A lens (control).

Is NCT03360110 still recruiting?

NCT03360110 is currently completed. Last updated 2 September 2020.

Are results published for NCT03360110?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-02 · How we verify

NCT03360110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of New Contact Lens With Current Marketed Lens

Completed NA Results posted Last updated 2 September 2020

What this trial tests

NA trial testing Phoebe test lens in Myopia in 53 participants. Completed in 15 December 2017.

Timeline

6 November 2017

Primary endpoint
15 December 2017

15 December 2017

Quick facts

Lead sponsor	CooperVision, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	53
Start date	6 November 2017
Primary completion	15 December 2017
Estimated completion	15 December 2017
Sites	1 location across United States

Drugs / interventions tested

Phoebe test lens
stenfilcon A lens (control)

Conditions studied

Myopia — all drugs for Myopia →

Sponsor

CooperVision, Inc.

Who can join

Adults 18 to 35, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Corneal Staining Extent Primary · Baseline

Measurement of extent of corneal staining using Fluorescein, blue light, yellow filter, full beam, medium magnification on a scale 0-4 (0=no staining, 1 = 1-15% of area, 2= 16-30% of area, 3=31-45% of area, 4=\>45% of area).

Group	Value	95% CI
Phoebe Test Lens	0.04	± 0.09
Stenfilcon A Control Lens	0.04	± 0.09

Corneal Staining Extent Primary · Day 3

Group	Value	95% CI
Phoebe Test Lens	0.07	± 0.13
Stenfilcon A Control Lens	0.07	± 0.12

Conjunctival Staining Score Primary · Baseline

Amount of staining observed on the conjunctiva scored 0-4 (0=none, 4=Deep Confluent, in 0.50 steps

Group	Value	95% CI
Phoebe Test Lens	0.18	± 0.21
Stenfilcon A Control Lens	0.18	± 0.21

Conjunctival Staining Score Primary · Day 3

Amount of staining observed on the conjunctiva scored 0-4 (0=none, 4=Deep Confluent, in 0.50 steps

Group	Value	95% CI
Phoebe Test Lens	0.26	± 0.26
Stenfilcon A Control Lens	0.29	± 0.28

Palpebral Hyperemia on Upper Lid Primary · Baseline

Measurement of hyperemia of the palpebral conjunctiva; graded 0-4 (0=none, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Upper Lid	0.96	± 0.39
Stenfilcon A Control Lens: Upper Lid	0.96	± 0.39

Palpebral Hyperemia on Upper Lid Primary · Day 3

Measurement of hyperemia of the palpebral conjunctiva; graded 0-4 (0=none, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Upper Lid	1.05	± 0.40
Stenfilcon A Control Lens: Upper Lid	1.06	± 0.38

Palpebral Hyperemia on Lower Lid Primary · Baseline

Measurement of hyperemia of the palpebral conjunctiva; graded 0-4 (0=none, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Lower Lid	0.96	± 0.39
Stenfilcon A Control Lens: Lower Lid	0.96	± 0.39

Palpebral Hyperemia on Lower Lid Primary · Day 3

Measurement of hyperemia of the palpebral conjunctiva; graded 0-4 (0=none, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Lower Lid	1.05	± 0.40
Stenfilcon A Control Lens: Lower Lid	1.06	± 0.38

Palpebral Roughness Grade - Upper Lid Primary · Baseline

Measurement of smoothness of palpebral conjunctiva; graded 0-4 (0=smooth, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Upper Lid	1.09	± 0.51
Stenfilcon A Control Lens: Upper Lid	1.09	± 0.51

Palpebral Roughness Grade - Upper Lid Primary · Day 3

Measurement of smoothness of palpebral conjunctiva; graded 0-4 (0=smooth, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Upper Lid	1.26	± 0.53
Stenfilcon A Control Lens: Upper Lid	1.20	± 0.46

Palpebral Roughness Grade - Lower Lid Primary · Baseline

Measurement of smoothness of palpebral conjunctiva; graded 0-4 (0=smooth, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Lower Lid	1.07	± 0.50
Stenfilcon A Control Lens: Lower Lid	1.07	± 0.50

Palpebral Roughness Grade - Lower Lid Primary · Day 3

Measurement of smoothness of palpebral conjunctiva; graded 0-4 (0=smooth, 4=severe) in 0.25 steps

Group	Value	95% CI
Phoebe Test Lens: Lower Lid	1.23	± 0.52
Stenfilcon A Control Lens: Lower Lid	1.20	± 0.46

Sponsor's own description

The purpose of this study is to validate the clinical performance of a new contact lens design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
NCT07229365 — Children's Viewing Behavior · NA · recruiting

Other CooperVision, Inc. trials

Trials by the same sponsor.

NCT06817785 — Soft Lens Study: Biomedics 1 Day Extra Sphere and Clariti 1 Day Sphere · NA · completed
NCT06758076 — A Clinical Comparison of Two Soft Contact Lenses (C24-755) · NA · completed
NCT06590441 — Investigation of Wearing Compliance of Spectacles for Myopia Control · completed
NCT06609018 — Clinical Investigation of Buttermere (LENS 271) Soft Contact Lenses · NA · completed
NCT06611410 — 1 Week Crossover Study Between Two Soft Contact Lenses · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03360110 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CooperVision, Inc.
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03360110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03360110

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Myopia

Other CooperVision, Inc. trials

Verify against primary sources